• 1.

    KDIGO. Clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD, 2016.

  • 2.

    Block GA, et al.. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized controlled trials. JAMA 2017; 317:146155.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Parfrey PS, et al.. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet. J Clin Endocrinol Metab 2013; 98:48344844.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Chertow GM, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:24822494.

  • 5.

    Parfrey PS, et al.. The effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 2015; 10:791799.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Parfrey PS, et al.. Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin J Am Soc Nephrol 2016; 11:539546.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Moe SM, et al.. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol 2015; 26:14661475.

  • 8.

    Floege J, et al.. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial. Clin J Am Soc Nephrol 2015; 10:800807.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Bover J, et al.. Clinical and practical use of calcimimetics in dialyisis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2016; 11:161174.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Belozeroff V, et al.. Economic evaluation of cinacalcet in the United States: The EVOLVE trial. Value Health 2015; 18:10791087.

What Groups of Patients on Dialysis Who Have Secondary Hyperparathyroidism Might Not Benefit from Calcimimetics?

  • 1 Patrick Parfrey, MD, is professor with the John Lewis Paton Distinguished University Memorial University, St John’s, NL, Canada.
Restricted access
Save